Integrated Biosciences

Integrated Biosciences is an early-stage biotech innovator engineering a next-generation drug discovery platform for aging-related diseases. By integrating optogenetics for precise biological control, advanced chemistry, and AI trained on proprietary ultra-large aging datasets, the company aims to systematically explore previously inaccessible chemical space and identify novel therapeutic candidates. Founded in 2021 with strong academic roots from MIT's Jim Collins, the company is building a pipeline of small molecules and has recently strengthened its leadership with key appointments, positioning itself at the forefront of the emerging longevity therapeutics field.

Integrated platform combining optogenetics (for precise, dynamic control of biological targets), synthetic biology, chemistry, and artificial intelligence, fueled by proprietary ultra-large aging datasets to discover novel small molecule therapeutics.

Integrated Biosciences competes in the emerging longevity and AI-driven drug discovery sector, facing competition from other biotechs like Calico (Alphabet), Unity Biotechnology, and numerous AI-native drug discovery firms (e.g., Recursion, Insitro). Its key differentiator is the direct integration of optogenetics for high-fidelity data generation, which few, if any, competitors combine with AI at its core.